## Supplementary material

**Supplementary Table 1.** Details of the SARS-CoV-2 virus strains used in live-virus microneutralization test

WHO	Pango	Isolate	GISAID accession	GenBank
label	lineage		ID	accession ID
Wild-	В	hCoV-	EPI_ISL_407079	MZ934691
type		19/Finland/1/2020		
Alpha	B.1.1.7	hCoV-19/Finland/THL-	EPI_ISL_2590786	MZ944886
		202102301/2021		
Beta	B.1.351	hCoV-19/Finland/THL-	EPI_ISL_3471851	MZ944846
		202101018/2021		
Delta	B.1.617.2	hCoV-19/Finland/THL-	EPI_ISL_2557176	MZ945494
		202117309/2021		
Omicron	B.1.1.529	hCoV-19/Finland/THL-	EPI_ISL_8768822	OM393712
/BA.1		202126660/2021		

**Supplementary Figure 1.** Neutralizing potency of serum, calculated as the ratio of neutralizing activity (MNT titer) to the SARS-CoV-2 anti-spike antibody concentration (binding antibody unit (BAU)/ml) specific to the receptor binding domain, RBD-IgG (A) and full-length spike protein, SFL-IgG (B)) against WT SARS-CoV-2 in uninfected subjects after two doses of COVID-19 vaccine, Comirnaty (vaccine only, n=20) and in subjects with previous SARS-CoV-2 infection followed by one dose of COVID-19 vaccine, Comirnaty (hybrid immunity, n=29). Serum samples were collected 14 to 30 days and 22 to 85 days after last vaccination for vaccine only and hybrid immunity groups, respectively. Statistical significance was determined by Mann-Whitney test, P values are indicated.



